GlassScriptPhysician profile
Anthony Gunawan
NPI 1811543531
$13,498.37
in general payments reported to CMS, 2019-2025
30 companies · $1,575 in 2025
The $1,575 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,657 · 2022: $1,546 · 2023: $4,184 · 2024: $2,537 · 2025: $1,575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,821 · Travel and Lodging: $1,475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,820.87 |
| Travel and Lodging | $1,475.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $6,019.96 | 2021-2025 | Wavewriter Alpha Prime 16, Intracept, General - Therapies |
| Mml US, INC. | $1,690.82 | 2022-2025 | Reactiv8 |
| Medtronic, INC. | $1,117.24 | 2021-2025 | Intellis Adaptivestim, Inceptiv |
| Abbott Laboratories | $697.20 | 2022-2025 | Eterna, Aveir, Proclaim |
| Nalu Medical, INC. | $547.70 | 2022-2025 | Nalu Neurostimulation System |
| Collegium Pharmaceutical, INC. | $457.11 | 2021-2025 | Belbuca |
| Scilex Pharmaceuticals INC. | $439.58 | 2021-2024 | Ztlido |
| Vertex Pharmaceuticals Incorporated | $347.65 | 2024-2025 | |
| Almatica Pharma LLC | $313.25 | 2021-2023 | Gralise |
| Nevro Corp. | $300.84 | 2021 | |
| Abbvie INC. | $282.25 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $186.52 | 2021-2025 | Relistor |
| Relievant Medsystems, INC. | $170.85 | 2023 | Intracept |
| Amgen INC. | $142.19 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $125.00 | 2024 | Verquvo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Painteq LLC | $97.86 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $87.79 | 2021-2022 | |
| Horizon Therapeutics Plc | $80.59 | 2022 | |
| Globus Medical, INC. | $62.61 | 2025 | Omnia, Senza |
| Azurity Pharmaceuticals, INC. | $51.55 | 2024-2025 | Horizant |
| Valinor Pharma, LLC | $41.70 | 2023 | Movantik |
| Redhill Biopharma INC. | $39.48 | 2022 | |
| Averitas Pharma INC. | $37.54 | 2025 | Qutenza |
| Protega Pharmaceutials INC | $31.83 | 2023 | Roxybond |
| Kowa Pharmaceuticals America, INC. | $28.58 | 2022-2023 | Seglentis |
| Alnylam Pharmaceuticals INC. | $26.83 | 2024 | |
| Avanos Medical | $22.06 | 2024 | Standard Rf Disposables |
| Uswm, LLC | $18.10 | 2021 | |
| Forte Bio-Pharma LLC | $17.66 | 2022 | |
| Spr Therapeutics, INC | $16.03 | 2023 | Sprint Pns System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Gunawan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.